Introduction: Erythropoietin (EPO) has been identified as a neuroregenerative agent. We hypothesize that it may accelerate recovery after crush injury and may vary with crush severity.
Peripheral nerve injuries, particularly traumatic injuries, are a significant source of morbidity and pose a challenge for treating physicians faced with limited options for improving outcomes. 1, 2 There is an expanding body of evidence suggesting that erythropoietin (EPO), originally described based on its function as a hematopoietic cytokine, has additional effects as a mediator of neurotrophic and neuroregenerative processes. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] These encouraging findings have led to multiple reports of EPO improving or accelerating nerve recovery in both the central 11, [13] [14] [15] and peripheral nervous systems. [16] [17] [18] [19] [20] Evidence suggests this may in part be attributable to EPO inhibiting apoptosis, protecting against oxidative damage, and stimulating axonal outgrowth after injury through its effects on Schwann cells, 10 in addition to its promotion of angiogenesis. EPO is approved by the U.S. Food and Drug Administration and has a limited sideeffect profile, making it an attractive agent for translational studies of peripheral nerve injury.
Current clinical classification systems of peripheral nerve injury apply characteristics of individual neurons to entire nerves, with the axon either intact or severed, and the epineurium either preserved or compromised. [21] [22] [23] In reality, with thousands of individual neurons comprising a complex peripheral nerve, crush injury may result in subpopulations of intact axons adjacent to subpopulations of severed axons and a potential for drastic variability of structural compromise and functional impairment. The complex and varied nature of peripheral nerve injuries demands an experimental model that can evaluate treatments across a range of injury severities to determine which injury patterns are most likely to benefit from an intervention.
Patients with nerve injuries in the setting of limb trauma can present with identical findings and vastly different capacities to recover. As a candidate treatment for peripheral nerve trauma, it is important to evaluate the effects of EPO on peripheral nerve injuries of different severities. We studied a murine model of sciatic nerve crush injury with 3 distinct injuries of increasing force, termed mild, moderate, and severe crush. We previously found that EPO speeds functional recovery of animals after crush injury over a time course faster than would be observed through nerve regeneration. 19 This strongly suggests that EPO may be providing supportive protection of function to neurons that remain intact and unsevered but somehow nonfunctional. We therefore hypothesized that certain nerve crush injuries are amenable to EPO-mediated functional recovery, whereas others may be so severe that EPO would not be helpful. Still others would be so mild that they would not cause a functional deficit for which EPO may be helpful. Moreover, if EPO is effective at speeding recovery before neurons can regenerate, then we further hypothesized that there may be measurable differences in the amount of myelin in EPO-treated injuries. Because no current method for evaluating the severity of nerve injury in the sciatic nerve crush model is available, we developed a method of measuring the relative force delivered to the nerve and then measured the capacity of EPO to accelerate functional recovery with different severities of crush as a means to test our hypothesis.
METHODS
Murine Model of Peripheral Nerve Crush Injury. All animal procedures were approved by the University Committee on Animal Research (UCAR) at the University of Rochester. Ten-week-old female C57BL6/J mice (Jackson Laboratories, Bar Harbor, Maine), weighing between 20 and 25 g, were anesthesized by intraperitoneal injection of ketamine (60 mg/kg) and xylazine (4 mg/kg). Crush injury was induced as follows. Briefly, the left hindlimb was shaved, washed, and prepped with povidoneiodine, then incisions were made along the lateral length of the femur and through the iliotibial band to expose the sciatic nerve. Once exposed, either mild, moderate, or severe crush injury was induced using diagonal jawed forceps (for mild and moderate crush; Miltex 18-1107 Swiss Cilia Forceps; Integra Miltex, York, Pennsylvania) or a stainless-steel needle holder (for severe crush; Webster Needle Holders RH2560; V. Mueller, CareFusion Corp., San Diego, California), at a point proximal to the sciatic nerve trifurcation into the common fibular, tibial, and sural nerves. The crush was held for 30 seconds in all cases.
To quantify the force of the crush injury, pressure-sensitive film (Sensor Products, Inc., Madison, NJ) was used to determine the pressure generated by the surgical instruments. Using known forces, the film was calibrated to provide a linear curve of pixel density vs. pressure (in pascals), with an R 2 5 0.98883. ImageJ software (http://imagej. nih.gov; NIH, Bethesda, Maryland) was used to analyze all images. The 3 injury intensities, mild, moderate, and severe, were then recreated with the film resting between the forceps, and the postcrush changes in the film were analyzed for pixel density within the region of the forceps corresponding to the placement of the sciatic nerve. These densities were fit to the known curve to determine each pressure. Pressures are reported in mega-pascals (MPa); as a reference, 1 MPa is equal to approximately 145 pounds per square inch (PSI). Each intensity level was tested 3 times, and the averages of the groups were compared. These injuries correspond to 2.5 MPa (6 0.25 MPa), 4.9 MPa (6 0.18 MPa), and 9.5 MPa (6 1.03 MPa) for mild, moderate, and severe crush, respectively.
After the injury, a single 5-0 nylon suture (Ethicon, Inc., Somerville, New Jersey) was used to close the fascia, and 3 interrupted 5-0 sutures were used to close the skin incision. Mice were immediately returned to their cages and allowed free active motion and weight-bearing under the supervision of the university's veterinary staff. Subcutaneous buprenorphine (0.05 mg/kg) was given at the time of surgery and every 12 hours over the next 3 days for analgesia.
Erythropoietin Treatment. EPO [Epoetin Alfa (Procrit); Janssen Products, Horsham, Pennsylvania (National Drug Code 59676-310-00)] was randomly administered to half of the animals in each injury group immediately after the crush injury. The surgeon who administered EPO or saline control to animals was blinded at the time of administration by having EPO in 1 of 2 syringes and saline control in the other. Half of the animals received treatment from 1 syringe and were marked using eartagging methods as part of the university animal protocol. The remaining animals received saline injection and were marked accordingly. Randomization was only resolved after data were analyzed, and the researchers were blinded to the status of the animals during the entire experiment as part of this protocol. Group sizes are reported below for functional and histologic analysis. EPO was given at a dose of 5,000 units/kg, based on previous studies of EPO in animals and humans. 19, 20, 24, 25 The supply of EPO was refrigerated and then suspended in a 100-ll solution of sterile saline at the time of injection. The treatment was delivered by intraperitoneal injection in accordance with pharmacy and veterinary recommendations. Control animals were given intraperitoneal injections of 100 ll of sterile saline at equivalent time-points.
Functional Analysis Using Sciatic Function Index.
Walking track analysis was performed according to a previously described model that uses the sciatic function index (SFI) as a noninvasive means to monitor recovery after scatic nerve injury. 26 Briefly, mice were trained to walk along a confined corridor before injury, with different colored paint thinly applied to the injured and uninjured hindpaws. Before injury, and on days 1, 3, 7, 14, 21, and 28 post-injury, animals from the 3 injury groups were walked along the corridor until clear prints were made (minimum n 5 5 per severity per timepoint), which often required multiple attempts. This group was used to characterize the natural course of recovery after the 3 crush severities. In addition, separate cohorts of mice from the EPO and control groups were walked at days 1, 2, and 7 post-injury (minimum n 5 5 per severity per treatment per time-point). Our previous work showed effects of EPO treatment at time-points earlier than could be expected under classical models of nerve regeneration. 19 As such, we focused on the effects of EPO that occurred early without subjection to biases associated with handling fragile nerves soon after crush injury. Day 7 was chosen, given the most significant differences between groups in the untreated cohorts, with inclusion of days 1 and 2 post-injury to evaluate whether any changes occurred in the days immediately after injury and after treatment. We confined this portion of the study to early effects. Using digital calipers, the following 2 measurements were made from the prints: paw length (PL, the distance from the heel to the third toe) and toe spread (TS, the distance from the first to the fifth toe). Two measurements were made from separate prints on both the uninjured and injured side, and averages were used to calculate the SFI. Calculation of SFI was done using a previously described formula:
where ETS is experimental toe spread, NTS is normal toe spread, EPL is experimental paw length, and NPL is normal paw length.
Histology and Immunohistochemistry. Mice were euthanized on post-injury day (PID) 7 for histologic analysis of the injury site (n 5 3 per severity). Immediately after killing, sections of the sciatic nerve containing areas proximal and distal to the crush site were removed carefully, washed in cold phosphate-buffered saline (PBS), and fixed in 4% paraformaldehyde for 4 hours at 48C. Nerves were then embedded in paraffin, and serial 5-lm-thick cross-sections were taken 2 mm proximal to the crush site (proximal), at the crush site (crush), and 2 mm distal to the crush site (distal).
Immunofluorescence was performed on PID 7 using antibodies to myelin protein 0 (P 0 ; Cat. No. PZ0; Aves Lab; 1:1,000) or neurofilament (NF; Cat. No. NFH; Aves Lab; 1:1,000). The slides were pretreated with 0.01 M citrate buffer (pH 6.0) for antigen retrieval. Nonspecific blocking was performed with 1:20 diluted serum for 30 minutes. After overnight incubation at 48C with the primary antibody, the fluorescent-labeled secondary antibody was incubated for 1 hour. Staining for P 0 , a major constituent of myelin, was used to evaluate the myelination status of neurons within different areas around the crush site, whereas NF staining allowed for evaluation of neuron continuity. Computational image analysis was performed using ImageJ software with the cell counter plug-in to quantify the number of P 0 and NF-positive axons at PID 7. A minimum of 3 slides per level (proximal, crush, or distal) per treatment were analyzed, using sections from different animals. Reviewers were blinded to the study groups.
Electron Microscopy. On PID 3, the sciatic nerves were surgically exposed, gently excised, and picked up with tweezers at excision ends to avoid inducing ultrastructural artifact. The nerves were immediately immersed into a fixative containing 2.5% glutaraldehyde/4.0% paraformaldehyde in 0.1 M sodium cacodylate buffer, fixed for 24 hours at 48C, and post-fixed for 2.0 hours in a combination of 1.5% potassium ferrocyanide/1.0% osmium tetroxide in 0.1 M sodium cacodylate. Before processing, both ends of each nerve were trimmed away, and the remaining length of each nerve was dehydrated in a graded series of ethanol to 100%, transitioned into propylene oxide, infiltrated with Epon/Araldite resin overnight, embedded longitudinally in a mold containing fresh resin, and polymerized for 48 hours at 608C. Each nerve was cut at 1 lm and stained with toluidine blue to ascertain the specific region to be thin sectioned at 70 nm using a diamond knife and an ultramicrotome. The thin sections were placed onto 150-mesh carbon/polyvinyl formal resin nickel grids and examined using a transmission electron microscope (TEM; Model 7650; Hitachi Corporation, Tokyo, Japan) with an attached Gatan Erlangshen digital camera and DigitalMicrograph software.
Statistics. Results are presented as mean 6 standard deviation (SD). Comparison between SFI in the 3 injury groups without any treatment was done using 2-way analysis of variance (ANOVA) with Bonferroni correction for multiple comparisons. Differences in SFI between the EPO-and vehicletreated groups were analyzed using multiple t-tests with the Holm-Sidak method to correct for multiple comparisons. For all analyses, statistical significance was set at a 5 0.05. A power analysis was performed based on the differences in SFI found between groups with and without EPO in our previous work. 19 This analysis revealed a 35% difference between treatment groups. Based on this difference and a desired power level of >80%, we arrived at a minimum group size of 5 mice per group for functional outcomes. Our previous work had suggested that a group size of 3 would be sufficient for immunohistochemical studies.
RESULTS
Natural Course of Functional Recovery. There were immediate differences in the degree of functional impairment imparted by the 3 different crush intensities ( Fig. 1 ; n 5 3-5 mice per severity per time-point). A higher SFI indicates worse function. At PID 1, the mild crush group performed significantly better than either the moderate (mild 67.4 6 25.4, moderate 100.7 6 4.7; P < 0.05) or severe (mild 67.4 6 25.4, severe 102.5 6 11.1; P < 0.01) crush groups. The significant difference was maintained at PID 3 for mild vs. moderate (mild 39.0 6 20.7, moderate 98.4 6 8.0; P < 0.01) and mild vs. severe (mild 39.0 6 20.7, severe 95.7 6 14.9; P < 0.01) groups, at which point the mild crush group was already beginning to show functional improvement. There were no significant differences between the moderate and severe groups at these early time-points. By PID 7, the moderate crush group was beginning to show functional improvement and performed significantly better than the severe crush group (moderate 71.8 6 17.3, severe 104.3 6 15.6; P < 0.05), although it remained significantly worse functionally than the mild crush group (mild 29.2 6 17.6, moderate 71.8 6 17.3; P < 0.01). By PID 14, there were no significant differences between the functional status of the mild and moderate groups, although the severe crush group remained worse than either the mild (mild 18.7 6 12.0, severe 82.7 6 30.5; P < 0.01) or moderate (moderate 24.4 6 7.7, severe 82.7 6 30.5; P < 0.01) crush groups. At PID 21, the severe crush group was beginning to show functional recovery, but it was still significantly worse than either the mild (mild 6.2 6 0.7, severe 44.4 6 25.5; P < 0.05) or moderate (moderate 9.2 6 6.5; severe 44.4 6 25.5; P < 0.05) groups. There were no significant differences between any of the groups at PID 28.
EPO Accelerates Functional Recovery in Moderately
Crushed Nerves. Walking track analysis was performed before crush injury and at PIDs 1, 2, and 7 to assess the effects of EPO on early nerve regeneration after 3 severities of crush injury (minimum n 5 5 per severity per treatment per time-point) (Fig. 2) . Higher SFI indicates worse function, whereas lower SFI values correspond with better function. Significant improvement in SFI was seen at PID 7 in the moderate crush group treated with EPO, compared with vehicle-treated controls (saline 82.3 6 1.7, EPO 63.5 6 2.5; P < 0.05) (Fig.  2B) . No significant differences in SFI were seen after EPO treatment at PID 7 in either the mild (saline 29.9 6 5.6, EPO 24.2 6 5.0; Fig. 2A Fig. 2C ) crush groups.
EPO Increases P 0 and Neurofilament Counts in
Moderately Crushed Nerves. Given the functional benefits of EPO at PID 7 in moderately crushed nerves, histologic sections proximal to the crush site, at the crush site, and distal to the crush site were stained and quantified from moderately crushed nerves 7 days after injury (n 5 3 per severity per time-point) (Fig. 3 ). Antibodies to P 0 and NF were used to evaluate the underlying changes in myelination status and axon continuity in the moderately crushed group after either saline or EPO treatment. P 0 was assessed as a measure of the amount of intact myelin surrounding fibers in the crush-injured nerve. Treatment with EPO led to significant increases in the number of fibers positive for P 0 at the crush site (saline 696 6 49 fibers; EPO 1,784 6 16 fibers; P < 0.05), and distal to the crush site (saline 473 6 49 fibers, EPO 652 6 17 fibers; P < 0.05; Fig. 3A) . Changes in NF staining were seen only distal to the crush site (saline 1,487 6 201 fibers, EPO 2,221 6 80 fibers; P < 0.05), consistent with distal axon degeneration after injury (Fig. 3B) . The ratio of P 0 to NF staining was used as a proxy for the number of myelinated nerve fibers, and significant increases in this ratio were seen at the crush site in EPO-treated nerves (saline 23 6 2%, EPO 57 6 2%; P < 0.05).
EPO Increases Vascularization of Damaged Nerves.
Electron microscopy was performed on sections from moderately crushed nerves treated with EPO and saline at PID 3 to visualize differences in early ultrastructural changes after injury (Fig. 4) . In uninjured control nerves, normal-sized endothelial cells and red blood cells (RBCs) were seen in the vascular lumen, surrounded by organized layers of myelinated axons (Fig. 4A) . Fragments of damaged myelin were seen after crush injury in the EPOtreated group (arrowheads), which lined up adjacent to a branching blood vessel (Fig. 4B) . The FIGURE 1. Functional recovery varies according to crush severity. In untreated mice, walking track analysis was performed at various time-points after crush injury to track functional recovery, as indicated by the sciatic function index (SFI). A higher SFI indicates worse function. All 3 groups recover function by 28 days post-injury, and the severity of injury affected the time to recovery (*P < 0.05 between mild and moderate; † P < 0.05 between mild and severe; ‡ P < 0.05 between moderate and severe).
vessel in the EPO treatment group displayed increased diameter along with hypertrophied endothelial nuclei ( Fig. 4B and D) . Within the same specimen, there was also evidence of preserved myelin in some areas. Similarly, saline-treated nerves had varied evidence of myelin damage and myelin preservation, suggesting a mixed injury (Fig. 4C) . However, there was a notable absence of any branching or dilated vasculature. Comparisons between saline- (Fig. 4E ) and EPO-treated nerves (Fig. 4D) at the same magnification demonstrate the drastic effect of EPO on endothelial nuclei, which were notably enlarged after crush injury and EPO treatment.
DISCUSSION
We report the variable effects of a single early dose of EPO on nerve regeneration after different severities of sciatic crush injury. The results suggest that, in moderately crushed nerves, EPO accelerates functional recovery, which may be through local effects on myelination and vascular proliferation. These positive effects were not observed in either mild or severely injured nerves. The findings further suggest that there may be a critical injury severity for which EPO exerts beneficial effects on nerve regeneration, and that either too little or too much damage renders treatment ineffective.
Evaluating the effects of EPO on a murine model of variable nerve damage is critical to guiding its translation into clinical use. In practice, partially injured peripheral nerves, which have a variable capacity to heal, are some of the most common injuries encountered. Large and predictable functional benefits of EPO treatment for peripheral nerve injuries have been described. 16, 18, 19, 28 This study expands on the current literature by evaluating whether the degree of injury has an effect on the response to EPO, particularly at early time-points FIGURE 2. EPO treatment improves functional recovery in moderately crushed nerves. The sciatic function index (SFI) was determined at post-injury days 1, 2, and 7 in the 3 crush severities for both EPO-and saline-treated groups. Higher SFIs suggest worse function, whereas lower SFIs indicate better function. (A) No significant differences were seen between the 2 treatment groups after mild crush injury. By 7 days post-injury, both groups achieved almost full functional recovery. (B) EPO treatment resulted in significant improvement in SFI at 7 days post-injury in the moderate crush group, suggesting accelerated functional recovery. (C) No significant differences in SFI were seen in the severe crush groups after either EPO or vehicle treatment. White bars: saline-treated; black bars: EPO-treated (*P < 0.05). Quantitative histomorphometry was performed in cross-sections taken from the moderate crush group at 7 days post-injury. Sections were taken from sites proximal to the crush (proximal), at the crush site (crush), and distal to the crush site (distal), then stained for myelin protein 0 (P 0 ) or neurofilament (NF). (A) Significant increases in the number of P 0 -positive axons were observed at the crush site and distal to the crush site in EPO-treated nerves, suggesting EPO-mediated increases in myelination. (B) Significant increases in neurofilament were seen only distal to the crush site in EPO-treated nerves. (C) The ratio of P 0 -to NF-positive fibers was calculated as a proxy for the percentage of myelinated fibers. Significant increases in this ratio were seen at the crush site in the EPO treatment group, suggesting that EPO may act through increased myelination of axons around the crush site. White bars: saline-treated; black bars: EPO-treated (*P < 0.05).
after injury. Reports on the use of the sciatic nerve crush injury model have not rigorously defined the amount of force, and thus the amount of injury to the nerve. This is important in the scenario that partial nerve damage disrupts a variable number of nerve fibers depending on the intensity of injury. An appropriate translation to clinical applicability depends chiefly on an accurate characterization of the most suitable injury type for EPO treatment.
To address the need for an injury model of varying severity, we have described crushes of increasing severity, termed mild, moderate, and severe. These injuries have distinct patterns of recovery (Fig. 1) , and all groups regained normal function by 28 days after injury. Predictable functional recovery allows for investigations of interventions that may influence the time course of recovery in different injury severities. Importantly, the short time course in which full functional recovery can be achieved makes this an attractive model for laboratory use in which month-and year-long recoveries may burden limited resources. Further, the choice of animal species should be intentional in peripheral nerve experimentation. The C57BL6/J mouse species was chosen in this study due to its potential for genetic manipulation in future experiments and what may be revealed about underlying mechanisms. With genetic variants selectively missing EPO receptors in Schwann cells and neurons, experiments can be recreated to determine whether the positive effects from this study are lost without the receptor.
Much of the current literature on peripheral nerve injuries in humans has relied on classifications that fail to distinguish between subpopulations of neurons that may sustain differential degrees of injury. Instead, clinical classifications provide a picture of a uniformly injured nerve with each portion equally affected by the injury. [21] [22] [23] In actuality, crush injuries often induce non-uniform patterns of injury, with varying degrees of myelin disruption and differences between subpopulations of neurons. It is therefore possible that subpopulations of neurons may be amenable to pharmacologic treatments, with others not amenable. As we have shown in this study, EPO has the strongest effect on moderately injured nerves. It may be possible that mildly injured nerves have not undergone sufficient injury for the effects of EPO to be functionally significant, whereas severely crushed nerves have too few salvageable fibers for EPO to demonstrate a significant effect. The injury for which EPO is likely to contribute the most functional benefit is therefore confined by factors not currently assessed in our clinical classification schemes.
Along with the functional benefits of EPO seen 7 days after injury in moderately crushed nerves (Fig. 2B) , there was an associated increase in the ratio of P 0 to NF seen on immunohistochemistry (Fig. 3) . These findings are consistent with previously reported effects of EPO on Schwann cells and myelination. Schwann cells express a receptor for EPO, which may be responsible for the beneficial effects of EPO administration. 5 EPO stimulates Schwann cell migration, and its administration has been shown to have a positive effect on myelination. 11, 13 These beneficial effects of EPO on myelination have already been translated into clinical trials for demyelinating diseases such as multiple sclerosis 15 and amyotrophic lateral sclerosis.
14 Results from studies on EPO administration after peripheral nerve injury suggest that there may be a role for its use in these types of injuries as well. High-magnification imaging using TEM allowed for ultrastructural comparisons between the EPO and control groups 3 days after moderate crush injury (Fig. 4) . These higher magnification images suggest the mixed injury pattern described earlier, in which areas of damaged and degraded myelin (arrowheads) are near areas of myelin preservation (arrows). The most notable observations were the increased diameter of capillary lumens infiltrating the crushed nerve (Fig. 4B) , along with hypertrophied endothelial nuclei relative to control-treated nerves (Fig. 4D) . Endothelial cell nuclei increase in size during periods of proliferation. In a study of sciatic nerve crush injury in rats, Podhajsky and Myers 29 observed endothelial nuclei swelling 1 week after crush injury. In our study, the same changes were observed, although at a much earlier time-point, suggesting that EPO may accelerate the normal physiologic response to crush injury.
In our model of differential degrees of sciatic nerve crush injury, all animals recovered function by 28 days, and temporal patterns of recovery varied according to injury severity (Fig. 1) . We chose early time-points for evaluation because the most significant differences in recovery occur within the first week after injury. Therefore, the effects appear to be partly through increased myelination of neurons that are temporarily disrupted but still maintain the capacity to regain function. This is further supported by the absence of any differences in neurofilament counts between the 2 treatment groups proximal to and at the crush site 7 days after injury (Fig. 3B) . The ability for EPO to promote axonal regrowth after nerve injury has been described previously 3, 4, 20 ; however, such a mechanism is unlikely to be responsible for the early effects seen in our study.
This study is limited, because it is difficult to quantify the effect of different crush intensities on the degree of disruption of myelination and of neurofilament continuity. Moreover, it is difficult to generalize the findings in this murine model to the traumatic nerve injuries encountered in humans. Specifically, the findings presented here do not address the effects of EPO in promoting recovery after nerve transection, which is the injury pattern perhaps most in need of treatments than can improve regeneration. A further limitation of this study is the use of the SFI. Although the SFI is often utilized, there is a natural selection for the very best possible footprints, which is part of this method. Our study is no exception. Our animals were typically walked down the track 2-3 times per trial. This was done before any selection of footprints for analysis. We believe that this means that we gave each animal the best opportunity to walk on its foot as normally as it could before the analysis. We avoided systematic bias in this process by performing our analyses in a blinded fashion. However, the standard method of SFI assessment naturally allows for a bias toward the best possible walking that an animal can perform on any given day. Yet another limitation of this study is the selection of time-points for functional evaluation in the first week. We chose functional evaluations at posttreatment and operative days 1, 2, and 7, primarily because our preliminary work showed a treatment effect in the first week after injury. This effect was greatest in animals treated on the day of injury, although it was significant for animals treated the day before and the day after injury. We recognized that it would have been optimal to evaluate animals daily, with cohorts euthanized and analyzed histologically every day. However, our functional evaluation was confined to the first 48 hours after injury, followed by measurements at 1 week to compare results with our previous work. An additional limitation is the absence of NF and P 0 counts from uninjured nerves, which would have provided an additional point of useful comparison. Little can be said about the functional status of myelin simply based on the positive staining with P 0 . Simple P 0 positivity does not guarantee that the myelin is functional. A functional myelin sheath encircles a single neurofilament, and electron microscopy would be required to ensure that more neurofilaments are myelinated in the setting of EPO treatment. We do not have these definitive data, but rather we have only a suggestion that EPO increases myelin content in the nerve. Nonetheless, this model is a standard method for comparison and evaluation of treatments in the literature and has the benefit of offering histopathological correlates of function in a relatively simple surgical system.
In the past, crush injuries of the sciatic nerve have been used to study functional impairment and recovery. Little is known about the relative effects that crush injury has on myelin at the site of crush, or on neurons proximal or distal to the site. We attempted to vary the severity of crush injury in this study, but we realized that, without an absolute measure of myelin content and NF staining, our relative assessments only pertain to the injury site and the areas proximal and distal to the site. We cannot make absolute assessments about myelin and its natural recovery after injury, as we did not study those effects. However, our results suggest that a study of myelin over time, in the hours after injury using this model, is warranted. Severity of injury, even when measured, may not be strictly reproducible. In our own experiments we found that severely injured animals treated with saline in 1 experiment fared differently than the severely injured animals evaluated at a different time of the year. We can say that even the mildest injury caused functional deficits, and these were highly reproducible in our hands. Our most severe crush injuries were more variable, and we attribute this to the relatively few fibers left intact after injury. If we suppose there were injuries where only 6%-10% of fibers remained intact to function afterward, then a 1% difference in this amount between animals would represent an 18% change in neuronal fibers traversing the injury site. We believe that the most severe injuries severed all but about 5% of fibers, and this may explain the wide variation observed in these experiments. Without a single standard for injury severity in crush models, we believe that severity is a limitation in any experiment on sciatic nerve crush injury, and our results should be interpreted with caution.
In conclusion, the results from this study suggest that EPO accelerates functional recovery after moderate crush injury and may act primarily on intact fibers with damaged but not fully compromised myelin through a myelin-protective mechanism. Future research is indicated to further describe the mechanisms responsible for the early changes in moderately injured nerves and to identify the long-term effects of EPO on functional recovery.
